This study is currently recruiting patients. Sponsored by Ligand Pharmaceuticals. The purpose of this study is to compare the effectiveness of 2 dose levels of ONTAK (denileukin diftitox) in treating patients who have recurrent or persistent cutaneous T-cell lymphoma.
Study ID Numbers: 93-04-11
ClinicalTrials.gov Identifier: NCT00050999
COPYRIGHT 2005 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2005 Gale Group